Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korean Pharma Earnings Roundup: Companies Struggled In First Quarter Because of April Price Cuts And Tightened Regulatory Grip On Rebates

This article was originally published in PharmAsia News

Executive Summary

As widely expected, top Korean companies were badly hit during the first quarter by April price cuts and a continuing government crackdown on rebates.

You may also be interested in...



Green Cross And MNC-Linked Daewoong Stand Out In Korea's Sluggish 3rd Quarter

SEOUL - South Korea's top five pharma companies - excluding Green Cross and Daewoong Pharmaceutical - posted sluggish sales in the third quarter, most of them still finding ways to cope with the government's tightening grip on their business practices

South Korean Pharmas Clamber For Partnerships To Survive Rapidly Changing Environment

SEOUL - South Korea's local pharmas are clambering to tie the knot with multinationals and among themselves in what appears to be a "marriage of necessity" in a desperate attempt to survive a government crackdown on rebates, on which locals have long depended

GSK Expands In Korea With Purchase Of 9.9 Percent Equity Stake In Dong-A Pharma

SEOUL - GlaxoSmithKline is paying KRW142.9 billion ($128.7 million) to acquire a 9.9 percent stake in South Korea's leading Dong-A pharmaceutical and OTC company. The strategic alliance should help GSK gain market share in the rapidly growing Korean pharmaceutical market

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel